U.S. Markets close in 5 hrs 17 mins

Nanophase Reports Third Quarter 2019 Financial Results

Announces 56% Growth for Year-Over-Year Formulated Product Sales

The Company’s financial conference call is scheduled for November 15, 2019 at 4pm EST

ROMEOVILLE, Ill., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Nanophase Technologies Corporation (NANX), a leader in minerals-based personal care ingredients and formulated products for protecting skin from environmental aggressors, such as UV light and pollution, today reported financial results for the third quarter and nine-month periods ended September 30, 2019. 

“The growth driver in 2019 has been Solésence. We continue to be optimistic about the future of the business and about the growing demand for minerals-based sunscreens generally.  There has been no slowing down of any of the trends we’ve seen. We had fourteen new launches through September 2019, and reorders for the first eight products we launched in 2018. We expect similar, or greater, Solésence growth through 2020,” said Jess Jankowski, the Company’s President and CEO.  “Revenue from our largest Personal Care Ingredients customer was down through September, and will be down year-over-year. The comparative reduction was driven from 2018 'spot-buys,' inventory builds, and the loss of a significant downstream customer. This was offset to an extent by a successful new product launch through our largest customer, which we expect to continue to grow in 2020.”

Third Quarter 2019 Financial Highlights

  • Revenue for the third quarter was $3.1 million in 2019 compared to $4.0 million in 2018. 
  • The net loss for the second quarter was $0.9 million, or $0.02 per share, in 2019, compared to a net loss of $0.1 million in 2018, or $0.00 per share, for 2018.

Nine Months Ended September 30, 2019 Financial Highlights

  • Revenue for the first nine months of 2019 and 2018 was $10.1 million and $11.0 million respectively. 
  • The net loss for the first nine months of 2019 was $2.0 million, or $(0.06) per share, compared to a net loss of $1.0 million, or $(0.03) per share, for the comparable period of 2018. 
  • The Company finished the quarter with approximately $1.0 million in cash and cash equivalents.

Jankowski continued, “While Solésence has had excellent revenue growth during 2019, margins have been lower than anticipated due to inefficiencies in handling higher volume. We will have much more installed filling capacity by year-end to allow more efficient production. Additionally, our product mix should be more favorable as we focus on margin improvement.

“Our November 13, 2019 financing, from a strong advocate of our Nanophase and Solésence businesses, has supported us in our recovery from the revenue decline from our largest customer.  We are now focused on building our margins on both new and existing business, with additional growth being important, but secondary to achieving the self-sufficiency that profitability will bring.” Mr. Jankowski reiterated, “Capturing more margin, and having it drop to the bottom line is our top focus today.

“Our Solésence® finished products and our Personal Care Ingredients are in high demand by the market.   We believe the continued growth of our Solésence business will demonstrate this through 2020, and we expect growth in all of our minerals-based products and ingredients over the coming years.”

Shareholders and members of the financial community are encouraged to participate in the upcoming conference call, where Mr. Jankowski will discuss the Company’s current and long-term prospects.

Third Quarter 2019 Conference Call
The Nanophase conference call, to be hosted by Jess Jankowski, the Company’s President & CEO, is scheduled for November 15, 2019, at 3:00 p.m. CST, 4:00 p.m. EST. The conference call dial-in number for U.S. callers is 877-312-8776 and for international callers is 408-774-4007.  The conference ID is 5570428.  Please dial in to the conference at least five minutes before the call is scheduled to begin.

The call may also be accessed through the Company’s website, at www.nanophase.com, by clicking on Investor Relations, Investor News and the link in the conference call announcement release.

Use of Non-GAAP Financial Information
Nanophase believes that the presentation of results excluding certain items, such as non-cash equity compensation charges, provides meaningful supplemental information to both management and investors, facilitating the evaluation of performance across reporting periods. The Company uses these non-GAAP measures for internal planning and reporting purposes. These non-GAAP measures are not in accordance with, or an alternative for, generally accepted accounting principles and may be different from non-GAAP measures used by other companies. The presentation of this additional information is not meant to be considered in isolation or as a substitute for net income or net income per share prepared in accordance with generally accepted accounting principles.

About Nanophase Technologies
Nanophase Technologies Corporation (NANX), www.nanophase.com, is a leader in minerals-based personal care ingredients and formulated products for protecting skin from environmental aggressors, such as UV light and pollution, as well as providing solutions for industrial product applications. Using a platform of patented and proprietary integrated technologies, the Company creates products with unique performance attributes from two ISO 9001 and ISO 14001 registered facilities. Nanophase delivers commercial quantity and quality engineered materials both as ingredients, and as part of fully formulated products, in a variety of formats.

Forward-Looking Statements
This press release contains words such as “expects,” ”shall,” “will,” “believes,” and similar expressions that are intended to identify forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements in this announcement are made based on the Company’s current beliefs, known events and circumstances at the time of publication, and as such, are subject in the future to unforeseen risks and uncertainties that could cause the Company’s results of operations, performance and achievements to differ materially from current expectations expressed in, or implied by, these forward-looking statements. These risks and uncertainties include, without limitation, the following: a decision by a customer to cancel a purchase order or supply agreement in light of the Company’s dependence on a limited number of key customers; uncertain demand for, and acceptance of, the Company’s nanocrystalline materials; the Company’s manufacturing capacity and product mix flexibility in light of customer demand; the Company’s limited marketing experience; changes in development and distribution relationships; the impact of competitive products and technologies; the Company’s dependence on patents and protection of proprietary information; the resolution of litigation in which the Company may become involved; the impact of any potential new government regulations that could be difficult to respond to or too costly to comply with while remaining financially viable; the ability of the Company to maintain an appropriate electronic trading venue; and other factors described in the Company’s Form 10-K filed April 4, 2019. In addition, the Company’s forward-looking statements could be affected by general industry and market conditions and growth rates. Except as required by federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.


NANOPHASE TECHNOLOGIES CORPORATION
 
CONSOLIDATED BALANCE SHEETS
(Unaudited Consolidated Condensed)
       
       
  September 30,   December 31,
ASSETS 2019   2018
       
Current assets:      
Cash and cash equivalents $ 962,182     $ 1,345,492  
Trade accounts receivable, less allowance for doubtful accounts      
of $9,000 on September 30, 2019 and on December 31, 2018   1,373,053       828,417  
Inventories, net   2,143,974       2,242,228  
Prepaid expenses and other current assets   285,011       273,235  
Total current assets   4,764,220       4,689,372  
       
Equipment and leasehold improvements, net   2,164,202       1,864,881  
Operating lease right-of-use assets   2,198,066       -  
Other assets, net   13,094       14,928  
  $ 9,139,582     $ 6,569,181  
       
LIABILITIES AND STOCKHOLDERS' EQUITY      
Current liabilities:      
Line of credit, LB&T $ 500,000     $ -  
Line of credit, related party   1,102,708       832,272  
Current portion of finance lease obligations   228,281       218,203  
Current portion of operating lease obligations   360,691       -  
Accounts payable   994,339       1,607,406  
Accrued expenses   960,516       979,243  
Deferred revenue   469,226       -  
Total current liabilities   4,615,761       3,637,124  
       
Long-term portion of finance lease obligations   333,990       506,006  
Long-term portion of operating lease obligations   2,128,036       500,000  
Long-term loan, related party   500,000       -  
Long-term deferred rent   -       343,867  
Long-term deferred revenue   125,000       -  
Asset retirement obligations   204,212       198,184  
Total long-term liabilities   3,291,238       1,548,057  
       
       
Stockholders' equity:      
Preferred stock, $.01 par value, 24,088 shares authorized and      
no shares issued and outstanding   -       -  
Common stock, $.01 par value, 42,000,000 shares authorized; 38,136,792 and 33,911,792      
shares issued and outstanding on September 30, 2019 and December 31, 2018, respectively   381,368       339,117  
Additional paid-in capital   100,623,516       98,795,105  
Accumulated deficit   (99,772,301 )     (97,750,222 )
Total stockholders' equity   1,232,583       1,384,000  
  $ 9,139,582     $ 6,569,181  
       


NANOPHASE TECHNOLOGIES CORPORATION
               
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited Consolidated Condensed)
               
  Three months ended   Nine months ended
  September 30,   September 30,
  2019   2018   2019   2018
Revenue:              
Product revenue, net $ 3,043,036     $ 3,997,526     $ 9,796,944     $ 10,907,659  
Other revenue   26,350       24,028       321,058       128,221  
Net revenue   3,069,386       4,021,554       10,118,002       11,035,880  
               
Operating expense:              
Cost of revenue   2,506,720       2,964,159       7,839,443       8,164,050  
Gross profit   562,666       1,057,395       2,278,559       2,871,830  
               
Research and development expense   487,798       415,724       1,449,646       1,512,453  
Selling, general and administrative expense   889,659       765,567       2,710,710       2,299,339  
Income/(Loss) from operations   (814,791 )     (123,896 )     (1,881,797 )     (939,962 )
Interest income   -       -       -       -  
Interest expense   47,139       11,741       140,282       31,641  
Other, net   -       -       -       -  
Income/(Loss) before provision for income taxes   (861,930 )     (135,637 )     (2,022,079 )     (971,603 )
Provision for income taxes   -       -       -       -  
Net income/(loss) $ (861,930 )   $ (135,637 )   $ (2,022,079 )   $ (971,603 )
               
               
Net income/(loss) per share- basic and diluted $ (0.02 )   $ -     $ (0.06 )   $ (0.03 )
               
Weighted average number of basic and diluted              
common shares outstanding   38,136,792       33,879,097       36,077,257       33,858,184  
               
               
               
               
NANOPHASE TECHNOLOGIES CORPORATION
               
CONSOLIDATED STATEMENTS OF OPERATIONS - EXPANDED SCHEDULE
(Unaudited Consolidated Condensed)
               
  Three months ended   Nine months ended
  September 30,   September 30,
  2019   2018   2019   2018
Revenue:              
Product revenue, net $ 3,043,036     $ 3,997,526     $ 9,796,944     $ 10,907,659  
Other revenue   26,350       24,028       321,058       128,221  
Net revenue   3,069,386       4,021,554       10,118,002       11,035,880  
               
Operating expense:              
Cost of revenue detail:              
Depreciation   61,612       59,253       181,494       194,293  
Non-Cash equity compensation   13,297       8,831       33,609       21,767  
Other costs of revenue   2,431,811       2,896,075       7,624,340       7,947,990  
Cost of revenue   2,506,720       2,964,159       7,839,443       8,164,050  
Gross profit   562,666       1,057,395       2,278,559       2,871,830  
               
Research and development expense detail:              
Depreciation   12,250       9,597       36,699       29,179  
Non-Cash equity compensation   15,804       15,373       42,196       22,373  
Other research and development expense   459,744       390,754       1,370,751       1,460,901  
Research and development expense   487,798       415,724       1,449,646       1,512,453  
               
Selling, general and administrative expense detail:            
Depreciation and amortization   5,159       4,881       15,948       15,308  
Non-Cash equity compensation   34,746       34,295       103,414       85,742  
Other selling, general and administrative expense   849,754       726,391       2,591,348       2,198,289  
Selling, general and administrative expense   889,659       765,567       2,710,710       2,299,339  
Income/(Loss) from operations   (814,791 )     (123,896 )     (1,881,797 )     (939,962 )
Interest income   -       -           -  
Interest expense   47,139       11,741       140,282       31,641  
Other, net   -       -           -  
Income/(Loss) before provision for income taxes   (861,930 )     (135,637 )     (2,022,079 )     (971,603 )
Provision for income taxes   -       -       -       -  
Net income/(loss) $ (861,930 )   $ (135,637 )   $ (2,022,079 )   $ (971,603 )
               
Non-GAAP Disclosure (see note regarding Non-GAAP disclosures):            
Addback Interest, net   47,139       11,741       140,282       31,641  
Addback Depreciation/Amortization   79,021       73,731       234,141       238,780  
Addback Non-Cash Equity Compensation   63,847       58,499       179,219       129,882  
               
Adjusted EBITDA $ (671,923 )   $ 8,334     $ (1,468,437 )   $ (571,300 )
               


COMPANY CONTACT
Investor Relations
630-771-6705